Factor Xa inhibitors have transformed anticoagulation, but urgent bleeding or surgery may require decisions before clinicians know when the last dose was taken or how much anticoagulant activity remains.

Join experts Alex Spyropoulos, Eduardo Ramacciotti, and Preston Hewgley as they discuss:

• Why residual factor Xa inhibitor activity matters in urgent care

• How an unknown last dose complicates clinical decisions

• Why bleeding risk persists despite DOAC advantages over warfarin

• How to balance bleeding, thrombosis, and surgical urgency

Tune in now and subscribe to Clot, Clot, Who’s There? for more expert conversations in thrombosis, hemostasis, and vascular medicine. 

00:00: Residual Factor Xa Activity: Why It Matters

01:38: Unknown Last Doses and Urgent Decisions

09:47: Major Bleeding and Urgent Surgery

14:03: Reversal, Treatment Delays, and Outcomes

Thank you to our sponsor, VarmX, for their generous support of this podcast episode. 

Check out the companion learning course, No Time To Wait: Urgent Surgery in Patients on Factor Xa Inhibitors, here.